Proving Capability: Dossiers, Interviews, and the Qualification Visit

Evidence bundle—not a questionnaire alone. A site feasibility questionnaire (SFQ) is necessary but insufficient. Request a Site Capability Dossier with documents you will later file in the Trial Master File (TMF):

• PI and Sub-I CVs (signed/dated), medical licenses, board certifications, GCP training dates.
• Delegation model and coverage plan; organizational chart for the study team.
• Pharmacy SOP excerpts (receipt, storage, dispensing, returns, destruction), temperature-monitoring procedure, excursion management, and equipment calibration certificates.
• Laboratory certifications (e.g., CLIA or national equivalent), reference ranges, shipping SOPs, and stability packaging.
• Imaging accreditation and sample acquisition manuals; ability to push to central reads.
• Data privacy policies (HIPAA/GDPR/UK-GDPR), IT security posture, EMR/eSource access controls, and data retention timelines.
• Recruitment assets: clinic volumes, referral agreements, historical prescreen logs (de-identified), community partnerships.
• Prior audits/inspections summary and CAPA effectiveness evidence.

Financial disclosure and conflicts. In the U.S., investigators must provide financial disclosure per 21 CFR Part 54 to support regulator assessments of potential bias; similar conflict-of-interest expectations exist under EU/UK frameworks. Collect disclosures at selection and refresh as required; store with other regulatory docs recognizable to the FDA and coherent to EMA reviewers.

Qualification conversations. Conduct structured interviews with the PI, coordinator, pharmacist, and data manager to validate dossier claims. Probe: (1) who will actually approach patients; (2) expected screening/consent cadence; (3) handling of complex eligibility; (4) ePRO and device workflows; (5) emergency coverage and after-hours IP access; (6) SAE reporting pathways; (7) data entry timelines; and (8) competing study load.

On-site or remote Site Qualification Visit (SQV). Use the SQV to corroborate facilities, storage, and documentation practices. Walk the “participant journey” from prescreen → consent → eligibility confirmation → dosing/procedure → endpoint capture. Confirm that physical layouts support privacy, blinded procedures, and safe IP/device handling. For remote SQVs, request live video walk-throughs and high-resolution photos of storage, alarm panels, and calibration stickers; follow with a short on-site check for high-risk trials.

Digital and decentralized readiness. Review:

• eConsent/eCOA: device availability, language sets, offline capture, timestamp integrity, and audit trails.
• Telemedicine: platform security, documentation of remote source, and SOPs for identity verification.
• Direct-to-patient IP: courier networks, neutral packaging, chain-of-custody, and temperature monitoring.
• Home health: nurse credentialing, procedure checklists, waste handling, and adverse event escalation.

Radiation, device, and invasive procedure oversight. If the protocol includes radiation or device use, verify permits and device-specific training, maintenance, and calibration. For invasive procedures, ask for credentialing lists and complication management SOPs. These checks map to regulator expectations across PMDA and TGA as well as FDA/EMA.

Decision and conditions of selection. Summarize the SQV in a risk-scored report with conditions precedent (e.g., “install backup freezer; complete blinded-assessment training; finalize referral MOU”). Provide the site a punch-list and target dates; selection is “conditional” until mitigations are verified and documented.

Readiness to Activate: Controls, Agreements, and People Who Can Deliver

Staffing that matches the protocol. Confirm the headcount and named alternates for roles that drive quality: PI and Sub-Is, coordinator(s), pharmacist, rater(s), data entry, imaging technologist, safety contact, and home-health liaison. Collect the delegation-of-duties log template and verify the site’s practice of maintaining training matrices that map each person to the procedures they perform.

Training and competency. Agree on role-specific training before the Site Initiation Visit (SIV): blinded assessment procedures; ePRO use and back-up; infusion/compounding SOPs; IP accountability and excursion response; adverse event and SUSAR reporting; endpoint acquisition manuals. Record attendance, competency checks (e.g., image phantom tests or mock draws), and remediation plans—artifacts later filed in the TMF and recognizable across agencies.

Contracts and budgets aligned with feasibility. Compensation should reflect protocol complexity—time-intensive visits, sedation monitoring, out-of-window make-ups, language services, and home-health coordination. Clear pass-through schedules for couriers, scans, and central lab shipping reduce cost disputes that derail timelines. Ensure budgets include equity accommodations (transport, childcare, devices) when needed to support fair access consistent with the WHO public-health ethos.

Regulatory/ethics readiness. Confirm IRB/IEC processes (central vs. local), country-specific submissions, radiation or device notifications, import/export licenses, and data-hosting restrictions. Sites must be able to operate within these constraints without improvisation. Synchronize consent packages and language approvals early to avoid activation drift.

Pharmacy and device control. Require documentation of receipt, storage, accountability, and destruction workflows. Validate temperature mapping, alarms, excursion SOPs (including quarantine, impact assessment, and disposition), and periodic calibration. For devices, confirm firmware/version control, preventive maintenance schedules, and blinding protections (e.g., display covers, standardized indicators).

Endpoint capture infrastructure. Ensure imaging parameters, central read upload pathways, rater certification, and eCOA configuration are tested in UAT with the site. For PK/PD studies, verify sample processing (centrifuge specs, timers, labeling printers), chain-of-custody, and pick-up windows. For surgery/infusion, confirm pre-procedure checklists and post-procedure observation capacity.

Data privacy and security. Validate SOPs for eSource/EMR access, role-based permissions, audit trails, and retention. For DCT elements, ensure encryption and data residency align with HIPAA/GDPR/UK-GDPR. Sites should know incident response escalation and breach notification timelines.

Risk-based quality management (RBQM) at selection time. Define site-level Key Risk Indicators (KRIs) and Quality Tolerance Limits (QTLs) tied to CtQ factors—for example, ≥95% primary endpoint on time; ≤2% eligibility misclassification; temperature excursion rate ≤1 per 100 IP days; SAE reporting within 24 hours. Capture these in the Monitoring Plan so the first monitoring visit can focus on the highest risks.

Vendor integration at the site. If the site will interface with central labs, imaging readers, home-health providers, couriers, or eCOA vendors, verify contact trees, shipping kits, labels, and support SLAs. The site must know who to call, when, and for what issue; the sponsor must know how performance will be measured and fed back.

Oversight Blueprint: KPIs, Early Warning Signals, and an Audit-Ready File Plan

Measure what predicts success, not just activity. Post-selection, track operational Key Performance Indicators (KPIs) that correlate with trial quality and speed:

• Enrollment productivity: eligible→approached→consented→randomized funnel per month and reasons for leakage.
• Timing fidelity: proportion of critical assessments within window; heaping near window edges; median lateness.
• Data quality: query aging, missing critical fields, ePRO completion, and device/sensor uptime.
• Safety responsiveness: time from AE onset to entry and from SAE awareness to initial report; narrative completeness.
• Compliance: deviation rates by category and recurrence after CAPA; temperature excursion incidence; unblinding events.

Centralized monitoring that uses KRIs in real time. Build dashboards that surface outliers against KRIs/QTLs and trigger targeted remote/on-site visits. Examples: sudden drop in diary completion; spike in late primary endpoints; pattern of eligibility clarifications; repeated “near-miss” temperature spikes. Tie triggers to pre-agreed actions (coaching, additional staffing, equipment service, temporary recruitment pause).

Performance management that is fair and fast. Share KPI scorecards with sites monthly. Celebrate wins and address risks with specific CAPA plans: “add Saturday slots for Week-12 visits,” “assign dedicated pharmacist back-up,” “activate community referral MOU.” When sites cannot meet conditions after support, off-board respectfully with documented rationale; redeploy participants to stronger sites where ethics and logistics allow.

Documentation that proves suitability throughout. Organize the TMF to tell the site-selection story end-to-end:

• Feasibility plan and CtQ matrix derived from protocol/estimand.
• Country and site feasibility questionnaires and Site Capability Dossiers.
• SQV agenda, reports, photos, and conditional selection letters with punch-lists.
• Investigator CVs/licenses/training, 21 CFR Part 54 financial disclosures (or regional equivalents), delegation logs, and coverage plans.
• Pharmacy/device documentation (temperature mapping, calibration, excursion logs, firmware versions).
• Endpoint infrastructure proofs (imaging accreditation, rater certifications, eCOA UAT evidence).
• Monitoring Plan with site-specific KRIs/QTLs; KPI dashboards; CAPA records and effectiveness checks.
• Correspondence with regulators/ethics as required—artifacts understandable to FDA, EMA, PMDA, TGA, and anchored in ICH principles.

Common pitfalls—and how to preempt them.

• Over-reliance on reputation: require dossier evidence and KPI history; verify competing study load and coordinator turnover.
• Unfunded burdens: budgets that ignore home-health, language services, or evening hours will undercut retention and timing.
• Thin pharmacy controls: insist on alarms with off-hours notification, excursion SOPs with quarantine, and periodic calibration proof.
• eCOA/eConsent misfires: confirm device provision and offline capture; run pilot UAT before SIV; monitor completion by subgroup.
• Imaging variability: standardize sequences; require phantom tests; central reader feedback loops.
• Equity blind spots: track approach rates by language/age; provide interpreters/devices; schedule around work and school hours.

Actionable checklist (concise).

• Capability profile built from CtQ factors; must-have vs. mitigatable gaps documented with owners and dates.
• Evidence-based access: eligible prevalence, approach/consent rates, referral network MOUs.
• Quality signals verified: prior audits, deviation patterns, on-time primary endpoint history, ePRO completion, query aging.
• Pharmacy/device readiness: temp mapping, alarms, excursion SOPs, calibration/maintenance, blinded displays.
• Digital/DCT readiness: eConsent/eCOA UAT, telemedicine SOPs, courier/home-health integration, data privacy compliance (HIPAA/GDPR/UK-GDPR).
• Training and delegation mapped to procedures; competency checks recorded.
• KRIs/QTLs defined pre-activation; monitoring dashboards built; trigger-action table approved.
• TMF organized to reconstruct suitability decisions quickly with artifacts recognizable to FDA, EMA, ICH, WHO, PMDA, and TGA.

Bottom line. Great sites are selected, proven, and supported—not merely recruited. When you anchor selection to CtQ factors, demand auditable evidence, condition your choices on mitigations, and run oversight with meaningful KPIs and KRIs, you secure an investigator network that protects participants, preserves your endpoints, and withstands inspection across the U.S., EU/UK, Japan, and Australia.